lenalidomide,tafasitamab
morphosys,incyte
['lymphoma', 'dlbcl', 'l-mind', 'incyte']
#news: incyte s late-breaking oral presentation at the highlights 5-year results from the l-mind study in patients with relapsed/refractory diffuse large b-cell lymphoma (#dlbcl). learn more. #aacr23
Incyte’s official Twitter. Ready to Solve On. See our Community Guidelines: https://t.co/DD2VZaemus